Humanin 10mg

Research

Scientific Research on Humanin
Humanin is an endogenous mitochondrial peptide first described in 2001 in experimental models associated with Alzheimer's disease. It is a small bioactive peptide derived from a small open reading frame (sORF) located in mitochondrial DNA, specifically within the 16S rRNA gene (MT-RNR2).
Humanin belongs to the class of MDPs (Mitochondria-Derived Peptides), which also includes MOTS-c and SHLPs (Small Humanin-Like Peptides). Its scientific interest stems from cytoprotective, anti-apoptotic, and metabolic properties, with implications in aging, neurodegenerative diseases, metabolism, and experimental oncology.
The classical human form consists of 24 amino acids when translated in the cytoplasm, although mitochondrial variants of 21 amino acids have also been described.

Mechanism of Action and Inhibition

Humanin acts through intracellular and extracellular mechanisms.
1. Intracellular mechanism (anti-apoptotic)
Humanin can directly interact with pro-apoptotic Bcl-2 family proteins, including:

• BAX
• tBid
  This interaction prevents BAX translocation to mitochondria and reduces outer mitochondrial membrane permeabilization, inhibiting cytochrome c release and caspase cascade activation.

2. Extracellular mechanism (receptor-mediated)
   Humanin may act as a ligand for a trimeric receptor complex composed of:

• CNTFR (Ciliary Neurotrophic Factor Receptor)
• WSX-1 (IL-27 receptor α)
• gp130
  Activation of this complex may trigger:
• STAT3 activation
• ERK1/2 activation
• JAK/STAT-dependent cytoprotective signaling

Additionally, studies suggest interaction with FPRL1 receptor (formyl peptide receptor-like 1), also known as FPR2, implicated in inflammatory responses.
No evidence exists of direct enzymatic inhibitory function; its action is predominantly modulatory and cytoprotective.

Scientifically Investigated Metabolic Impacts

Experimental studies indicate Humanin may influence multiple metabolic axes:
1. Insulin sensitivity

• Improved insulin signaling in murine models
• Reduction of diet-induced insulin resistance
• Potential PI3K/Akt pathway modulation

2. Mitochondrial metabolism

• Protection against oxidative stress
• Preservation of mitochondrial function
• Reduction of reactive oxygen species (ROS)

3. Aging
   Plasma Humanin concentrations tend to decrease with age in experimental models, suggesting possible regulatory role in cellular aging.

Investigation in Oncological Models

Humanin exhibits complex role in experimental oncology.
Potential pro-tumor survival effects:
Due to its anti-apoptotic activity, hypotheses suggest it may:

• Protect tumor cells against cell death
• Reduce chemotherapeutic efficacy in certain contexts

Potential protective metabolic effects:
Conversely, its ability to improve mitochondrial function and modulate oxidative stress may have indirect implications in tumor biology.
Currently, no consensus exists on its definitive role as pro- or anti-tumor factor; data remain contextual and model-dependent.

Pharmacokinetic Considerations in Research

Pharmacokinetic data remain predominantly experimental.
Observed characteristics:

• Subcutaneous or intraperitoneal administration in animal models
• Relatively short half-life
• Possible rapid systemic clearance
• Proteolytic degradation sensitivity

Synthetic modified analogs (e.g., HNG – Humanin G, with S14G substitution) demonstrated greater biological potency in experimental models.

Other Important Existing Research Relationships

• Alzheimer's disease and neuroprotection
• Parkinson's disease (experimental models)
• Type 2 diabetes
• Cardiovascular diseases
• Sarcopenia
• Systemic aging
  Humanin is considered a mitochondrial mediator with relevant role in mitochondria-nucleus communication (retrograde signaling).

Final Considerations

Humanin is a mitochondrial DNA-derived peptide with widely investigated cytoprotective and anti-apoptotic properties in experimental models. It acts both through direct interaction with pro-apoptotic proteins and receptor-mediated JAK/STAT signaling.
Its metabolic effects include improved insulin sensitivity and protection against oxidative stress. In oncology, its role remains ambiguous given its potential anti-apoptotic effect.
Humanin represents an emerging field in mitochondrial biology and aging/metabolic disease research.

References

Hashimoto, Y., Niikura, T., Tajima, H., et al. (2001). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Proceedings of the National Academy of Sciences, 98(11), 6336–6341. https://doi.org/10.1073/pnas.101133498
Guo, B., Zhai, D., Cabezas, E., et al. (2003). Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature, 423(6938), 456–461. https://doi.org/10.1038/nature01627
Muzumdar, R. H., Huffman, D. M., Calvert, J. W., et al. (2009). Humanin: a novel central regulator of peripheral insulin action. PLoS ONE, 4(7), e6334. https://doi.org/10.1371/journal.pone.0006334
Cobb, L. J., Lee, C., Xiao, J., et al. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging, 8(4), 796–809. https://doi.org/10.18632/aging.100943
Lee, C., Yen, K., & Cohen, P. (2013). Humanin: a harbinger of mitochondrial-derived peptides? Trends in Endocrinology & Metabolism, 24(5), 222–228. https://doi.org/10.1016/j.tem.2013.01.005

Scientific Reviewer
Content reviewed by Dr. Ky H. Le, MD. Dr. Ky H. Le is a family physician in Aiea, Hawaii. He received his medical degree from St. George's University School of Medicine and has been practicing for over 20 years. He has expertise in treating obesity, diabetes, hypertension, and high blood pressure, among other conditions—see all areas of specialization. Dr. Ky H. Le accepts Medicare, Aetna, Humana, Blue Cross, United Healthcare.
Ref.: https://health.usnews.com/doctors/ky-le-371599#expertise